Benzinga's Top #PreMarket Losers

fell 29.45 percent to $14.83 in pre-market trading on beloranib partial clinical hold.

shares fell 9.33 percent to $66.88 in pre-market trading on its earnings report. Earnings of $0.86 per share came in below $0.88 estimate; revenue of $996.29 million fell short of expectations for earnings around $1.03 billion.

shares declined 5.88 percent to $208.60 in pre-market trading after the company reported downbeat Q3 earnings and lowered its FY15 forecast.

shares tumbled 4.35 percent to $39.18 in pre-market trading after the company priced 5.5 million share offering for gross proceeds of $211.8 million.

shares dipped 0.51 percent to $1.96 in pre-market trading. AMD reported a wider-than-expected loss for the third quarter, but the company's revenue exceeded analysts' expectations. The company also announced a new joint venture with China's Nantong Fujitsu Microelectronics and a corporate restructuring plan aimed at reducing operating expenses.